Novel RGD-lipid conjugate-modified liposomes for enhancing siRNA delivery in human retinal pigment epithelial cells by Chen, Cheng-Wei et al.
© 2011 Chen et al, publisher and licensee Dove Medical Press Ltd.   This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of Nanomedicine 2011:6 2567–2580
International Journal of Nanomedicine Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
2567
OrIgINAL reseArCh
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/IJN.S24447
Novel RGD-lipid conjugate-modified liposomes 
for enhancing sirNA delivery in human retinal 
pigment epithelial cells
Cheng-Wei Chen1
Da-Wen Lu2
Ming-Kung Yeh3
Chia-Yang shiau4
Chiao-hsi Chiang1,5
1graduate Institute of Life sciences, 
2Department of Ophthalmology,  
Tri-service general hospital, 
3Institution of Preventive Medicine, 
4graduate Institute of Medical 
sciences, 5school of Pharmacy, 
National Defense Medical Center, 
Neihu, Taipei, Taiwan
Correspondence: Chiao-hsi Chiang 
school of Pharmacy National Defense 
Medical Center, 161 Minchuan e rd, 
sec 6 Neihu, Taipei 11490, Taiwan 
Tel +88 62 8792 3100 ext 18894 
Fax +88 62 8792 4838 
email cch@ndmctsgh.edu.tw
Background: Human retinal pigment epithelial cells are promising target sites for small 
  interfering RNA (siRNA) that might be used for the prevention and/or treatment of   choroidal 
  neovascularization by inhibiting the expression of angiogenic factor; for example, by 
  downregulating expression of the vascular endothelial growth factor gene.
Methods: A novel functional lipid, DSPE-PEG-RGD, a Arg(R)-Gly(G)-Asp(D) motif peptide 
conjugated to 1, 2-distearoyl-sn-glycero-3-phosphoethanolamine- N-[maleimide (polyethylene 
glycol)-2000], was synthesized for the preparation of siRNA-loaded RGD-PEGylated lipo-
somes to enhance uptake of encapsulated siRNA in retinal pigment epithelial cells. Various lipo-
somes, with 1 mol% and 5 mol% PEGylated lipid or 1 mol% and 5 mol% RGD-PEGylated 
lipid, were fabricated.
Results: Characterization of the liposomes, including siRNA entrapment efficiency, 
  average   particle size and ζ-potential, were determined to be as follows: .96%, 129.7 ± 51 
to 230.7 ± 60.7 nm, and 17.3 ± 0.6 to 32 ± 1.3 mV , respectively. For the in vitro retinal 
  pigment epithelial cell studies, the RGD-PEGylated liposomes had high delivery efficiency 
with siRNA delivery, about a four-fold increase compared with the PEGylated liposomes. 
  Comparison of the various liposomes showed that the 1 mol% RGD-modified liposome had 
less   cytotoxicity and higher siRNA delivery efficiency than the other liposomes. The antibody 
blocking assay   confirmed that uptake of the 1 mol% RGD-PEGylated liposome was via integrin 
  receptor-mediated endocytosis in retinal pigment epithelial cells.
Conclusion: The results of this study suggest that RGD-PEGylated liposomes might be 
useful for siRNA delivery into retinal pigment epithelial cells by integrin receptor-medicated 
endocytosis.
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Introduction
Gene therapy is thought to have great potential for treatment of acquired diseases, as 
well as inherited genetic diseases.1 Many human diseases, eg, cancer and neovascu-
larization, have been associated with overexpression of specific genes. The delivery 
of a normally functioning gene to the nucleus or cytoplasm of malfunctioning cells, 
may restore the targeted abnormal gene to a normal state.2,3 Human retinal pigment 
epithelial cells play an important role in angiogenesis of the choroid by overexpression 
of angiogenic factors. Small interfering RNA (siRNA) is a double-stranded structure 
with 21–23 base pairs that can target its complementary mRNA, thereby hastening 
mRNA degradation, and inhibiting translation of a targeted gene.4–6 With high speci-
ficity and easy application, siRNA has gradually replaced more   conventional gene 
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knockdown techniques for target-specific gene silencing. 
The ability of siRNA to silence gene expression has become 
a useful tool for investigating gene function; in addition, 
it is used in the pharmaceutical industry to develop phar-
macological agents.7 Thus, retinal pigment epithelial cells 
might be a promising target site for siRNA used to prevent 
or treat choroidal neovascularization in patients with age-
related macular degeneration by inhibiting expression of 
angiogenic factor. However, use of siRNA as a therapeutic 
agent has been complicated by problems such as poor for-
mulation stability, difficulty penetrating biological barriers, 
and low delivery efficiency at the target site. Therefore, it 
is important to develop a delivery system that serves as an 
effective vector for siRNA and provides optimal delivery to 
the targeted site.6,8
Cationic liposomes are a promising nonviral delivery 
system, and have been extensively studied for siRNA and 
plasmid DNA delivery.9 The addition of polyethylene gly-
col (PEG) to the liposomes can decrease reticuloendothelial 
system recognition, thereby prolonging the circulation time 
in biological fluids. Although PEGylated liposomes provide 
a more stable preparation, the steric barrier of the grafted 
PEG moiety on the surface of the liposomes reduces interac-
tion between the delivery system and the cell surface. Many 
strategies have been successfully implemented to improve 
cell delivery efficiency of the PEGylated nanoparticles includ-
ing transient PEG coating, attachment of targeting ligands 
at the distal end of PEG moieties, and the incorporation of 
cell-penetrating peptides.10,11 Currently, liposome studies are 
focusing on targeting delivery to maximize the delivery of the 
carried therapeutic agent to the targeting site and minimizing 
potential side effects. The addition of specific antibodies or a 
biological adhesive cell ligand to the liposome can enhance 
its binding ability in specific tissues, cells or pathogens, and 
consequently achieve higher delivery efficiency. For enhanc-
ing siRNA delivery into retinal pigment epithelial cells, the 
ligand of the surface receptors in the retinal pigment epithe-
lial cells might be used to modify the PEGylated lipid of the 
  liposome. Previous studies have shown that integrin receptors 
are upregulated in ocular neovascularization. Specifically, 
integrin αVβ3 is overexpressed in the ocular tissues of patients 
with age-related macular degeneration, whereas, αVβ3 and 
αVβ5 are also found in the vascular tissues of patients with 
proliferative diabetic retinopathy.12 Other studies showed that, 
in retinal pigment epithelial cells, the αVβ3 and αVβ5 receptors 
were expressed at the apical side, while integrin α5β1 receptors 
were expressed at the basolateral side.13 Expression of α5β1 
integrins on the basolateral side of retinal pigment epithelial 
cells has been characterized and shown to be important for 
attachment of cells to Bruch’s membrane. Expression of αVβ3 
and αVβ5 integrins at the apical side has been associated with 
maintenance of diurnal phagocytosis of the shed photorecep-
tor outer segment fragment.14 In order to enhance the delivery 
of siRNA-loaded liposomes to retinal pigment epithelial cells, 
liposomes with the integrin receptor ligand might be used to 
target delivery of siRNA to retinal pigment epithelial cells 
for the prevention and/or treatment of choroidal neovascu-
larization in patients with age-related macular degeneration. 
Moreover, peptides with the RGD motif have been shown to 
bind specifically to αV- or α5- associated integrins.15,16 Thus, 
modified liposomes with the RGD motif peptide might be 
constructed to carry siRNA for targeted delivery.
The purpose of this study was to synthesize a functional 
RGD peptide-lipid conjugate and develop an effective 
lipid-based gene vector associated with the RGD peptide for 
targeting integrin receptors and enhancing siRNA delivery 
to retinal pigment epithelial cells. In addition, the character-
ization, cytotoxicity, and delivery efficiency of the liposome 
preparations were investigated.
Materials and methods
Chemicals
A negative control siRNA or FAM-labeled negative con-
trol siRNA (having a molecular mass of approximately 
13.5 kDa, sense: FAM-5′-UUC-UCC-GAA-CGU-GUC- 
ACG-UTT-3′ and antisense: 5′-ACG-UGA-CAC-GUU-
CGG-AGA-ATT-3′) were purchased from MDBio Inc 
(Taipei, Taiwan). All of the lipid materials used, 3β-[N-(N′,N′-
dimethylaminoethane)-carbamoyl] cholesterol (DC-cho-
lesterol), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine 
(DOPE), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-
N-[carboxy (polyethylene glycol)-2000] [DSPE-PEG(2000) 
carboxy], and 1,2-distearoyl-sn-glycero-3-phosphoeth-
anolamine-N-[maleimide (polyethylene glycol)-2000] 
[DSPE-PEG(2000) maleimide] were obtained from Avanti 
Polar Lipids (Alabaster, AL). The RGD peptide (sequence: 
H-Gly-Arg-Gly-Asp-Ser-Pro-Lys-Cys-OH, molecular weight, 
818.9 Da) was purchased from Yao-Hong Biotechnology Inc 
(Taipei, Taiwan). CHCA (α-cyano-4-hydroxycinnamic acid) 
was obtained from Sigma-Aldrich (St Louis, MO). The SYBR 
Gold, Hoechst 33342, and BODIPY phalloidin dyes were 
obtained from Invitrogen (Eugene, OR). The MTS reagent, 
3-[4, 5-dimethylthiazol-2-yl]-5-(3-carboxymethoxyphenyl)-2- 
(4-sulfophenyl)-2H-tetrazolium, was purchased from Promega 
Corporation (Madison, WI). Anti-integrin antibodies (αVβ3, 
MAB1976; α5β1, MAB1969; α5, CBL497) were obtained from International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2569
rgD-Pegylated lipid conjugate for delivery of sirNA
Chemicon International (Temecula, CA). All other chemicals 
were pharmaceutical or reagent grade.
Synthesis and identification  
of DsPe-Peg(2000)-rgD
RGD peptide-conjugated DSPE-PEG(2000) maleimide 
[DSPE-PEG (2000)-RGD] was synthesized by modifying 
a method previously reported.17 Briefly, DSPE-PEG(2000) 
maleimide ammonium salt (molecular weight 2941.61) and 
RGD peptide were dissolved in a buffer solution (50 mM 
triethanolamine hydrochloride, 50 mM sodium phosphate, 
150 mM NaCl, and 1 mM EDTA, pH 8). DSPE-PEG(2000) 
maleimide solution (2 mM) was gently mixed with an equal 
volume of RGD peptide solution (4 mM) overnight in a 
glass bottle at 4°C. The synthesized product was identified 
by matrix-assisted laser desorption/ionization time-of-flight 
(MALDI-TOF) mass spectrometry (Bruker Daltonics, 
  Autoflex II TOF/TOF50, Leipzig, Germany).
Preparation of sirNA-loaded liposomes
PEGylated cationic liposomes, containing DC-cholesterol, 
DOPE, and DSPE-PEG(2000) carboxy with molar ratios of 
50/49/1 and 50/45/5, were prepared by the thin-film hydra-
tion method according to a method previously reported.18 
Briefly, the lipids were dissolved in chloroform in a rotary 
bottle (total lipids 3.6 µmol). After evaporation, a thin lipid 
film was formed and further dried under a vacuum for eight 
hours to remove residual solvent. The dry lipid film was 
hydrated for eight hours using 2.4 mL sterile phosphate-
buffered solution containing siRNA or FAM-labeled siRNA. 
The dispersion was sonicated for 10 minutes and then passed 
through a polycarbonate membrane 10 times (100 nm pore 
size) using an extruder (Avanti Polar Lipids, Mini-Extruder, 
Birmingham, AL). The total lipid concentration of the pre-
pared liposomes was 1.5 mM.
Preparation of sirNA-loaded liposomes 
with RGD peptide modification
RGD-modified PEGylated cationic liposomes, containing 
DC-cholesterol, DOPE, and DSPE-PEG(2000)-RGD, with 
molar ratios of 50/49/1 and 50/45/5, respectively, were 
  prepared. The procedure was the same as described above.
Characterization of sirNA-loaded 
liposomes
Particle size
The prepared siRNA-loaded liposomes (1.5 mM) were 
diluted to 1 mM using an appropriate volume of sterile 
phosphate-buffered solution (pH 7.3). The volume-average 
hydrodynamic diameter of various siRNA-loaded liposomes 
was determined by a dynamic light scattering method using 
a particle analyzer (Horiba Instruments Limited, LB-500, 
Tokyo, Japan). A laser diode was used for dynamic light scat-
tering, with a LB-550 software system from Horiba Instru-
ments Limited. The apparatus consisted of a digital correlator 
and a signal processor incorporated in a computer. Measure-
ments were made at 650 nm, at a 90° angle for the detector 
(photo multiplier tube). The mean particle size and size 
distribution of the siRNA-loaded liposomes were obtained 
for each sample measurement at room temperature.
Zeta potential
The prepared siRNA-loaded liposomes (1.5 mM) were diluted to 
1 mM using an appropriate volume of sterile phosphate-  buffered 
solution (pH 7.3). The zeta potential of the siRNA-loaded 
  liposomes was measured by determining the   electrophoretic 
mobility using the zeta potential analyzer (Brookhaven 
  Instruments, ZetaPlus, Long Island, NY) at room temperature. 
  Triplicate measurements were performed for each sample.
Transmission electron microscopy
For the transmission electron microscopy, the siRNA-
loaded liposome solution (8 µL) was placed on a formvar/
carbon film-coated copper grid, obtained from Ted Pella 
(Redding, CA). After removing excess sample with filter 
paper, the sample was air-dried for 10 minutes at room tem-
perature. The siRNA-loaded liposomes were then visualized 
using 0.5% uranyl acetate negative staining for 15 seconds 
at room temperature and imaged on a transmission electron 
microscope (Hitachi, H-7650, Tokyo, Japan). Images were 
taken at 50,000× magnification.
Entrapment efficiency
For determination of the entrapment efficiency of the PEGy-
lated liposomes and RGD peptide-modified PEGylated 
liposomes, the amount of negative control siRNA was quanti-
fied in the external phase, according to methods previously 
reported.19,20 The liposomes were spun down at 20,000 × g for 
30 minutes; the supernatants were diluted (if necessary), and 
stained with SYBR Gold dye and analyzed for siRNA content 
by measuring the intensity of fluorescence with an enzyme-
linked immunosorbent assay reader (Biochrom Ltd, Anthos 
2010, Cambridge, UK) at 537 nm against a standard curve. 
A standard curve was established from analyzing a series 
of siRNA reference solutions with 200 µL measured by an 
enzyme-linked immunosorbent assay reader, and determined International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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fluorescence intensity of 537 nm. The regression equations 
were as follows: y = 11.343x − 221.91, r square = 0.9992. 
The regression lines had good linearity, ranging from 31.25 
to 2000 ng/mL for siRNA. The entrapment efficiency of 
the siRNA-loaded liposomes was calculated as the ratio 
of siRNA used for preparation of the initial mixture as 
follows: Entrapment efficiency (%) = (siRNAt − siRNAf)/
siRNAt × 100; where siRNAt is the total amount of siRNA 
used for preparation of the initial mixture and siRNAf is the 
free siRNA amount recovered in the supernatant. All the 
measurements were done in triplicate.
ArPe-19 cell cultures
ARPE-19 cells were obtained from the American   Tissue 
  Culture Collection and cultured in a 1:1 mixture of   Dulbecco’s 
modified Eagle’s medium (DMEM) and Ham’s F12 with 
15 mM HEPES buffer, 2 mM L-glutamine, 56 mM sodium 
bicarbonate, and 10% fetal bovine serum. The cells were 
maintained at 37°C in a humidified atmosphere with 5% 
CO2.21 Cells in passages 25 to 32 were used in the experi-
ments, and seeding cells were counted in a hemocytometer 
with Trypan blue staining.
Liposomal cytotoxicity
ARPE-19 cells were seeded in 96-well plates at a density of 
1.6 × 104 cells per well and incubated for 18 hours. Before the 
MTS assay, cells were washed with phosphate-buffered solu-
tion 100 µL. A 1.5 mM total lipid concentration of the prepared 
liposomes was diluted to 51.2, 12.8, and 3.2 µM with serum-
free culture medium. The siRNA-loaded liposomes were then 
added to 100 µL of serum-free culture medium. After four 
hours, the cells were washed with phosphate-buffered solution 
100 µL, and 100 µL of the cultured media was then added. 
Next, the cells were added to 20 µL of MTS and incubated for 
two hours at 37°C. An enzyme-linked immunosorbent assay 
reader, set at 490 nm, was used to read the absorbance of for-
mazan in each well to determine the quantity of mitochondrial 
dehydrogenases in the viable cells. The percent cell viability 
was calculated as: cell viability (%) = [(ABSsample − ABSblank)/
(ABScontrol − ABSblank)] × 100, where ABSsample, ABScontrol, and 
ABSblank represent the absorbance of wells exposed to the 
liposomal dispersions, treated with serum-free culture medium, 
and treated with serum-free culture medium but without cells, 
respectively.22
Confocal laser scanning microscopy
The ARPE-19 cells were seeded in six-well plates using DMEM 
medium at a density of 2 × 105 cells per well and incubated for 
24 hours to achieve 50% confluence. Before the uptake study, 
the culture media was removed, and the cells were washed 
with phosphate-buffered solution. The   phosphate-buffered 
solution was then removed, and the   prepared FAM-siRNA 
loaded liposomes, in 1 mL of serum-free culture media, were 
added. After four hours, the cells were washed three times with 
phosphate-buffered solution. The cells were then fixed with 
3.7% formaldehyde for 10 minutes and washed three times 
with 1 mL of phosphate-buffered solution. Finally, cellular 
permeability was increased by adding 0.1% Triton for five 
minutes, and washing three times with 1 mL of phosphate-
buffered solution. The cells were incubated in Hoechst 33342 
for five minutes, which was then replaced by BODIPY phal-
loidin for 20 minutes. Confocal laser scanning microscopy 
(Jeol Ltd, Leica TCS SP5, Tokyo, Japan) was performed to 
obtain optical images of the distribution of FAM-siRNA in 
the ARPE-19 cells. Images obtained from the bottom of the 
coverslip to the top of the cells were recorded by confocal 
laser scanning microscopy (CLSM). The number of speckled 
green fluorescence images of the FAM-siRNA located within 
the cytoplasm was counted from the Z-series images at every 
1 µm of depth. For determination of the FAM-siRNA local-
ized within the cell, the number of speckled green fluorescence 
images counted was divided by total cell number observed in 
each image. The figure was determined by the distance of the 
Z-axis from the bottom of the coverslip versus the number of 
speckled green fluorescence (FAM-siRNA) images counted 
in the cytoplasm of each cell.
Flow cytometry
The ARPE-19 cells were seeded in six-well plates using 
DMEM medium at a density of 3 × 105 cells per well and 
incubated for 24 hours to achieve 75% confluence. Before 
the uptake study, the culture media was removed and the 
cells were washed with phosphate-buffered solution. FAM-
siRNA loaded liposomes in 1 mL of serum-free culture 
media were then added. After four hours, the cells were 
washed three times with phosphate-buffered solution and 
then detached using 0.05% trypsin/0.02% EDTA, washed 
with phosphate-buffered solution, and resuspended in 1 mL 
phosphate-buffered solution for flow cytometric assay. The 
FAM-siRNA loaded liposome uptake was measured using a 
flow cytometer (Becton Dickinson, FACScan flow cytom-
eter, Heidelberg, Germany). The ARPE-19 cells were then 
analyzed at 488 nm excitation and 530 nm band-pass filter 
in the emission path. Forward and side light scatter was used 
to gate the desired scattered events of the normal cells, dead 
cells, and cell debris.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Antibody blocking assay of FAM-sirNA 
loaded liposomes
Previous studies have shown that ARPE-19 overexpresses 
various integrins and serves as an in vitro cell model for gene 
delivery.23,24 In order to confirm that receptor-bearing cells take 
up the RGD-modified PEGylated liposome, ARPE-19 was 
incubated with FAM-siRNA-loaded 1 mol% RGD-PEGylated 
liposomes at 37°C. To determine that specific receptors were 
used in the uptake of 1 mol% RGD-PEGylated liposomes 
by ARPE-19, the cells were pretreated with antibodies that 
block αVβ3 (MAB1976), α5β1 (MAB1969), and α5 (CBL497) 
integrins. All antibodies were used at 5 µg/mL.25 The 
ARPE-19 cells were seeded in six-well plates using DMEM 
medium at a density of 3 × 105 cells per well and incubated 
for 24 hours to achieve 75% confluence. Before treating the 
FAM-siRNA loaded liposomes, the cells were preincubated 
separately with αVβ3 antibody, α5 antibody, or α5β1 antibody, 
for one hour and then FAM-siRNA loaded liposomes were 
added. After two hours, the cells were washed three times with 
phosphate-buffered solution and then detached using 0.05% 
trypsin/0.02% EDTA, washed with phosphate-buffered solu-
tion, and resuspended in 1 mL of phosphate-buffered solution 
for the flow cytometry assay.
statistical analysis
The results are expressed as the mean ± standard deviation. 
The Student’s t-test for the comparisons between two means 
was used to determine statistical significance. Differences 
were considered to be significant at P , 0.05.
Results
Synthesis and identification  
of DsPe-Peg-rgD
Under the reaction conditions of 12 hours at 4°C, pH 8, and 
gentle mixing, DSPE-PEG(2000)-RGD (molecular weight 
3741.69 Da) was successfully synthesized using DSPE-
PEG(2000) maleimide (molecular weight 2922.79 Da) and 
thiolated RGD peptide (molecular weight 818.9 Da), by a 
Michael additive reaction between activated maleimide and a 
thiol group (Figure 1A). Formation of the desired compound 
was further confirmed by the MALDI-TOF mass. Peaks of 
parental DSPE-PEG(2000) maleimide completely vanished 
and shifted to the right side, at regions approximating the 
molecular weight of the thiolated RGD peptide (Figure 1B). 
DSPE-PEG maleimide was not a homogenous polymer 
  compound. The successive members in DSPE-PEG(2000)-
RGD or DSPE-PEG(2000) maleimide differed in mass by 44 
Da for the ethylene oxide −CH2CH2O− molecular weight.
Characterization of sirNA-loaded 
liposomes
The characterization of the liposomes, including particle 
sizes, zeta potential, and entrapment efficiency, is summa-
rized in Table 1. The mean particle sizes for the 1 mol% and 
5 mol% PEGylated liposomes with siRNA were 129.7 nm 
and 147.2 nm, respectively. Mean particle size increased 
slightly by increasing the molar ratio of the PEGylated lipids. 
In addition, the RGD-PEGylated liposomes with siRNA had 
larger mean particle sizes than the PEGylated liposomes. The 
transmission electron microscopic images of the 1 mol% 
PEGylated liposomes and 1 mol% RGD-PEGylated lipo-
somes showed a similar particle size distribution as mea-
sured by the dynamic light scattering method (Figure 2A 
and B). The siRNA-loaded 1 mol% PEGylated liposome 
had the highest positive zeta potential (32 ± 1.34 mV) of all 
the liposomes studied. When a high molar ratio of DSPE-
PEG(2000) carboxy was incorporated, the zeta potential was 
reduced to 25.7 ± 1 mV for the 5 mol% PEGylated liposomes. 
In addition, incorporation with different molar ratios of the 
synthesized lipid, DSPE-PEG(2000)-RGD, reduced the zeta 
potential to 24.9 ± 1.5 for the 1 mol% RGD-PEGylated and 
to 17.3 ± 0.6 mV for the 5 mol% RGD-PEGylated liposomes. 
The PEGylated liposomes and RGD-PEGylated liposomes 
showed high-level siRNA entrapment efficiencies of more 
than 96% by the thin film hydration method.
Liposome cytotoxicity
The cytotoxicity of the liposome formulations was evaluated 
in the ARPE-19 cells with total liposomal lipid concentra-
tions of 3.2, 12.8, or 51.2 µM for the cells incubated with 
serum-free medium alone, no treatment with liposome as 
a control, and cell viability set at 100% (Figure 3). The 
viability of ARPE-19, the group treated with 12.8 µM of 1 
or 5 mol% RGD-PEGylated liposomal suspensions, showed 
a relative cell viability that remained unchanged. However, 
there was significantly reduced relative cell viability when 
the cells were treated with 12.8 µM of 1 mol% and 5 mol% 
PEGylated liposomes. There was no cytotoxicity among the 
groups treated with 3.2 µM, but significant cytotoxicity was 
observed with the 51.2 µM treatment. These results show that 
RGD peptide modification of cationic PEGylated liposomes 
was less cytotoxic than the cationic PEGylated liposomes.
CLsM imaging study
The distribution of FAM-siRNA-loaded liposomes was 
studied to determine their intracellular distribution with 
or without DSPE-PEG-RGD. Figure 4 shows the confocal International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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images of FAM-siRNA-loaded RGD-PEGylated lipo-
somes; they had a significantly greater amount of speckled 
green fluorescence (FAM-siRNA) in the ARPE-19 cells 
compared with the cationic PEGylated liposomes 
(4B . 4A, 4D . 4C). Slightly more FAM-siRNA was 
detected in the 1 mol% PEGylated liposomes compared 
with 5 mol% PEGylated liposomes (4A . 4C). These 
findings suggest that high levels of PEGylation in the 
liposomes decreased uptake of FAM-siRNA in the loaded 
liposomes. However, FAM-siRNA was significantly greater 
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in the 1 mol% RGD-PEGylated liposomes compared with 
the 5 mol% RGD-PEGylated liposomes (4B . 4D). A 
three-dimensional detection method was used by the CLSM 
for determination of FAM-siRNA loaded liposomes local-
ized within the cell. Comparison of 1 mol% PEGylated 
liposomes with 1 mol% RGD-PEGylated liposomes (Fig-
ure 5A and B) showed that the 1 mol% RGD-PEGylated 
liposomes were more localized than the 1 mol% PEGy-
lated liposomes (5B . 5A). The total number of 1 mol% 
PEGylated liposomes and 1 mol% RGD-PEGylated 
liposomes was counted as 40 and 89, respectively. These 
findings suggest that the RGD-PEGylated liposomes may 
provide an efficient transfer of siRNA for delivery into 
ARPE-19 cells.
Liposome uptake by ArPe-19 cells
The FAM-siRNA uptake intensity in the ARPE-19 cells 
was studied to evaluate the PEGylated liposomes and 
RGD-PEGylated liposomes; flow cytometry was used for 
the analysis. Comparison in the presence and absence of 
RGD-PEGylated effects in the formulation of 1 mol% and 
5 mol% RGD-PEGylated liposomes, showed FAM-siRNA 
delivery efficiencies of about 3.6 times and 4.2 times 
greater than for 1 mol% and 5 mol% PEGylated liposomes, 
respectively (Figure 6B and C). For the 1 mol% and 
5 mol% PEGylated liposomes, the FAM-siRNA delivery 
efficiency decreased as the percentage of PEGylated lipids 
increased in the   formulation. In the 1 mol% and 5 mol% 
RGD-PEGylated liposomes, the FAM-siRNA delivery 
efficiency was also decreased as the percentage of DSPE-
PEG-RGD increased in the formulation. Similar trends 
were observed in the results of the CLSM imaging study. 
These findings might be explained by the RGD peptide 
modification of the PEGylated liposomes enhancing the 
delivery efficiency of the cargo gene, FAM-siRNA, into 
the ARPE-19 cells. From the image of the forward and 
side light scatter, cell debris was significantly observed in 
the 5 mol% PEGylated liposomes, but was not obvious in 
the 5 mol% RGD-PEGylated liposomes. These findings 
suggest that the cationic PEGylated liposome with a higher 
percentage of PEGylated-lipids might have damaged the 
cell integrity (Figure 6A). However, RGD peptide modifica-
tion of the cationic PEGylated liposomes appears to have 
reduced damage to the integrity of the cell. These findings 
suggest that PEGylated lipid interferes with the integrity of 
the cell and that DSPE-PEG-RGD is less prone to induce 
cell damage.
Antibody blocking assay
Comparison of the uptake of FAM-siRNA loaded 1 mol% 
PEGylated liposomes of cells with or without antibody 
  pretreatment; the group without antibody pretreatment was 
used as a control, and the FAM-siRNA uptake intensity 
was set at 100%. The pretreatment of anti-αVβ3, -α5β1, 
or -α5 antibody uptake percentage was decreased to 23.2% 
(P , 0.01), 31.9% (P , 0.001), and 34.1% (P , 0.001), 
respectively (Figure 7). When pretreated with a mixture 
Table 1 Particle characterization of sirNA-loaded liposomes
Group Lipid molar ratio in formulation Zeta potential  
(mV)
Mean particle size  
(nm)
Entrapment  
efficiency (%)
1 mol% Pegylated liposome 50:49:1  
(DC-chol/DOPe/DsPe-Peg2000)
   32 ± 1.3‡ 129.7 (51)§ 97.66 ± 0.05‡
5 mol% Pegylated liposome 50:45:5  
(DC-chol/DOPe/DsPe-Peg2000)
25.3 ± 1 147.2 (48.2) 96.07 ± 0.07
1 mol% rgD-Pegylated liposome 50:49:1  
(DC-chol/DOPe/DsPe-Peg2000-rgD)
24.9 ± 1.5 156.4 (37.5) 98.83 ± 0.01
5 mol% rgD-Pegylated liposome 50:45:5  
(DC-chol/DOPe/DsPe-Peg2000-rgD)
17.3 ± 0.6 230.7 (60.7) 99.34 ± 0.03
Notes: ‡Data are the mean ± standard deviation for n = 3; §data are the mean (distribution width).
0.2 µm0 .2 µm
AB
Figure 2 Transmission electron microscopic images of sirNA-loaded liposomes. 
(A) sirNA-loaded 1 mol% Pegylated liposomes. (B) sirNA-loaded 1 mol% Pegylated, 
RGD peptide-modified liposomes. The images were taken at 50,000× magnification 
from the suspended liposomal particles after negative staining. In the bottom-right 
corner, the local image was enlarged to view the interface of liposomes clearly. 
Bar = 0.2 µm.
Abbreviations: sirNA, small interfering rNA; Peg, polyethylene glycol.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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have also been studied.29 However, previous studies have 
usually prepared the nanoparticles first, and then added a 
targeting molecule for conjugation on the surface of the 
nanoparticle.17,29,30 This method is limited by the difficulty in 
controlling the number of targeting moieties conjugated to 
the constructed nanoparticles. In this report, synthesis of the 
ligand-conjugated lipid, DSPE-PEG-RGD, was performed 
by Michael addition reactions between activated maleim-
ide and thiol groups prior to preparation of the liposomes 
(Figure 1A). The DSPE-PEG-RGD was easy to synthesize, 
allowing precise addition of the targeting molecule in a 
variety of liposome preparations. In this study,   MALDI-TOF 
mass spectrometry, a powerful tool for identification of a 
compound’s molecular weight, was used to determine the 
molecular weight of DSPE-PEG maleimide and DSPE-
PEG-RGD. MALDI-TOF mass spectrometry showed that 
the DSPE-PEG-RGD peaks all increased approximately 
818.9 Da, which is the molecular weight of thiolated RGD 
peptide, compared with the relative DSPE-PEG maleimide 
peaks (Figure 1B). After reaction, the parental DSPE-PEG 
maleimide peaks were almost gone, and instead DSPE-
PEG-RGD peaks were observed. These results showed that 
the DSPE-PEG maleimide reacted quantitatively with one 
thiolated RGD peptide.
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Figure 3 Cell viability of sirNA-loaded liposome preparations in ArPe-19 cells after four hours of treatment: The total lipid concentrations of sirNA-loaded liposome 
preparations investigated were 51.2, 12.8, and 3.2 µM.
Notes: Data are expressed as the mean ± standard deviation for n = 5. (student’s t-test *P , 0.05 or **P , 0.01 compared with the untreated group).
of -αVβ3, -α5β1, and -α5 antibodies, the uptake percentage 
was decreased to 49.5% (P , 0.001) compared with no pre-
treated antibody control. These data further confirmed that 
the RGD-PEGylated liposomes were internalized by integrin 
receptor-mediated endocytosis in ARPE-19 cells.
Discussion
Because it is difficult for free siRNA to enter into cells, 
lipid-based carriers are often used to improve cellular uptake 
of siRNA.26 Previous studies have reported that cationic 
liposomes can be used for gene delivery; they are easy to 
prepare, reasonably inexpensive, and can achieve ideal 
transfection.27,28 Currently, the targeting liposome design is 
of great interest for the transport of genes into desired target 
cells; this method has the potential to produce greater and 
more selective therapeutic activity. This approach involves 
the coupling of targeting moieties capable of recognizing 
target cells, binding to them, and internalization of the 
  liposomes and encapsulated gene. For this process, a   variety 
of targeting liposomes can be developed. For example, an 
antibody-mediated liposome, or an immunoliposome, can 
be constructed to target HER2-overexpressing tumors using 
anti-HER2 liposomes. Other ligands such as folate, transfer-
rin, RGD peptide, and the epidermal growth factor receptor International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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The PEG moiety of the liposome has been demonstrated 
to be more stable and remains in the circulation for a longer 
period of time in vivo, because the PEG moiety provides an 
efficient steric hindrance that prevents the binding of plasma 
proteins with the liposomes and thereby also interferes with 
uptake by the reticuloendothelial system.10,29,31 In this study, 
the zeta potential of the siRNA-loaded 1 mol% PEGylated 
liposome was highly positive (32 ± 1.3 mV). However, 
when a high molar ratio of DSPE-PEG was incorporated, 
it was reduced to 25.3 ± 1 mV for the 5 mol% PEGylated 
liposomes. Incorporating different molar ratios of DSPE-
PEG-RGD resulted in further reductions in the zeta potential 
to 24.9 ± 1.5 for the 1 mol% RGD-PEGylated liposomes 
and to 17.3 ± 0.6 mV for the 5 mol% RGD-PEGylated 
liposomes (Table 1). These findings show that the presence 
of a lipid-bound PEG moiety shielded the positive charge 
from the cationic lipid, and the presence of a RGD peptide 
at the end of PEG moiety shielded the molecule from a more 
positive charge.
In 1 mol% PEGylated liposomes and 1 mol% RGD-
  PEGylated liposomes, the hydrodynamic size was in the 
range of 129.7 to 156.4 nm, associated with a narrow size 
distribution of 51 to 37.5 nm, respectively. The presence of the 
RGD peptide on the liposome surface slightly increased the 
size compared with liposomes without the RGD peptide. 
Theoretically, for a 100 nm liposomal particle modified with 
DSPE-PEG2000, the PEG moiety is arranged in the mush-
room mode in the presence with ,4 mol% DSPE-PEG2000; 
the PEG moiety is configured in phase transition by the pres-
ence of a 4 to 8 mol% modification, and in the brush mode 
with .8 mol% PEGylation.32 The effect of grafted PEG on 
liposome size is mainly a change in the spatial structure of 
the DSPE-PEG molecule, which is contingent on the grafted 
PEG in the mushroom or brush configuration.33
The transmission electron microscopic assay showed 
clearly the image of the small unilamellar vesicles that 
comprise the lipid bilayer, with diameters in the range 
of 50–250 nm; a narrow size distribution was observed 
(  Figure 2). The small unilamellar vesicles contain a large 
aqueous core and are preferentially used for encapsulated 
water-soluble drugs.10 These findings indicate that the DSPE-
PEG-RGD incorporated into the liposome resulted in steri-
cally stabilized liposomes as well as PEGylated liposomes.
In this study, siRNA entrapment efficiencies were all 
higher than 96%. This was primarily due to the electro-
static interaction between the dimethylaminoethane of the 
DC-cholesterol and the phosphate groups of the siRNA in 
a +/− charge ratio of 4, consistent with previously reported 
findings from Zhang et al.34
Liposomes are composed of phospholipids and cho-
lesterols, which are components of the cell; these com-
pounds are biocompatible and nontoxic particulates that 
can be used for gene carrier constructs. However, there are 
some components reported that tend to be associated with 
cytotoxicity. For example, positively charged liposomes 
containing DC-cholesterol had increased toxicity when 
their dimethylaminoethane content was increased;35 the lipo-
some formulations included a lipid holding a PEG moiety 
to reduce the surface charge density of the cationic lipid. 
However, as the PEG molecular weight of the PEGylated 
nanoparticle increased, the cytotoxicity also increased.36 In 
this study, the cytotoxicity caused by the RGD-PEGylated 
liposome was lower than for the PEGylated liposome; these 
findings suggest that RGD peptide modification reduced 
the toxicity of the PEG   portion of the liposome structure. 
With the concentration of the RGD-PEGylated liposome in 
the culture medium less than 12.8 µM, the biosafety of the 
delivery system was improved in ARPE-19 cells (Figure 3). 
Hence, this safe concentration was used in the subsequent 
siRNA delivery assay.
AB
CD
100 µm
Figure 4 Fluorescence microscopic images showing the internalization of various 
FAM-sirNA-loaded liposomes in ArPe-19 cells, four hours after administration, at 
40× magnification: (A) 1 mol% Pegylated liposomes; (B) 1 mol% Pegylated, rgD 
peptide-modified liposomes; (C) 5 mol% Pegylated liposomes; (D) 5 mol% Pegylated, 
RGD peptide-modified liposomes. SiRNA was labeled with FAM (the arrows are 
added to point out the green sites), the cell nuclei were stained with hoechst 33342 
(blue), and the cell actin was stained with BODIPY phalloidin (red).
Abbreviations:  FAM,  fluorescein-labeled;  siRNA,  small  interfering  RNA;  PEG, 
polyethylene glycol; rgD, Arg(r)-gly(g)-Asp(D) motif peptide.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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The liposomal surface charge is considered one of the most 
important parameters governing cellular uptake of nanopar-
ticles, which occurs by the electrostatic interactions of oppo-
sitely charged cells and liposomes.37,38 PEGylated   liposomes 
decreased the uptake of the liposome and its cargo gene, 
FAM-siRNA (Figure 4A and C); this resulted from not only 
a lower positive charge on the liposome surface, but also 
the ability of the PEG moiety of the liposome to prevent 
contact with the cell surface. These properties minimize 
the nonspecific binding of liposomes to the cell surface.39,40 
However, in order to accumulate more liposomal siRNA in 
the retinal pigment epithelial cells, with the goal of producing 
greater and more selective therapeutic activity, use of active 
targeted liposomes with the RGD peptide has been suggested. 
This involves coupling RGD moieties capable of recognizing 
and binding to the integrin receptor of the retinal pigment 
epithelial cells, and then inducing liposome or loaded siRNA 
uptake. The expression of α5β1 integrins on the basolateral 
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Figure 5 Three-dimensional confocal images showing the intracellular location of FAM-sirNA-loaded liposomes (green) in ArPe-19 cells, four hours after administration, at 
100× magnification: 1 mol% PEGylated liposomes (top figure); 1 mol% RGD-PEGylated liposomes (bottom figure). The number of speckled green fluorescence images of FAM-
sirNA located within the cytoplasm were counted at each Z-series image (right of figure). The cell nuclei were stained with hoechst 33342 (blue), and the cell was stained with 
BODIPY phalloidin (red).
Abbreviations: FAM, fluorescein-labeled; siRNA, small interfering RNA; RGD, Arg(R)-Gly(G)-Asp(D) motif peptide.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 6 Various amounts of FAM-siRNA loaded liposome uptake as measured by flow cytometry. (A) Forward and side light scatter were used to gate the desired scattered 
events (normal cells) from dead cells and cell debris. (B) In the normal cells, uptake intensity of FAM-sirNA loaded liposome preparations (green histogram) was compared 
with the untreated control (block histogram). (C) Fluorescence intensity of FAM-sirNA-loaded liposome preparations in the normal cells expressed as an intensity ratio by 
dividing by the untreated control. 
Notes: Data are expressed as the mean ± sD for N = 3. (student’s t-test: *P , 0.01 or **P , 0.005, RGD peptide-modified liposomes compared with non-RGD peptide-
modified liposomes; 5 mol% compared with 1 mol%). 
Abbreviations: FAM, fluorescein-labeled; siRNA, small interfering RNA; SD, standard deviation.
side of retinal pigment epithelial cells has been characterized, 
and shown to be important for attachment of cells to Bruch’s 
membrane, while expression of the αVβ3 and αVβ5 integrins 
on the apical side maintains diurnal phagocytosis of the 
shed outer segment fragment of the photoreceptor.14 The 
RGD-containing peptide could be used as a specific ligand 
for integrin αVβ3, αVβ5, or α5β1. Therefore, the synthesized 
DPSE-PEG-RGD was used to formulate targeted liposomes 
in this study by covalent binding of the active maleimide of 
the PEG end and the specific thiol group of ligands.
For the siRNA, the interference mechanism is neces-
sary for successful delivery of siRNA into the cytoplasm International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Dovepress
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of target cells. In further analysis of the CLSM images, 
comparing the 1 mol% RGD-PEGylated liposomes with 
the 1 mol% PEGylated liposomes, the total number of 
1 mol% RGD-PEGylated liposomes localized within the 
cells was more than for the 1 mol% PEGylated liposomes 
(Figure 5A and B).   Therefore, a large amount of the 
FAM-siRNA-loaded 1 mol% RGD-PEGylated liposomes 
was confirmed to provide effective delivery into the cyto-
plasm of the ARPE-19 cells. However, siRNA delivery is 
a multistep process, which has several potential problems, 
including biological barriers to penetration, cellular inter-
nalization, endosomal escape, and cytoplasm trafficking.5,34 
In the future, the knockdown effect of targeted liposomes 
encapsulating a functional siRNA and the therapeutic 
effects in vivo of targeted delivery will require further 
evaluation.
Previous reports have shown that a suitable size and 
positive zeta potential are essential for enhanced delivery 
of particles into cells.41 The results of this study show that 
RGD-PEGylated liposomes have a larger size and smaller 
zeta potential, but increased siRNA delivery efficiency 
in ARPE-19 cells, compared with PEGylated liposomes 
(  Figure 6). Demonstrating further that binding was mediated 
by RGD-associated integrin receptors, the data from the 
integrin -αVβ3, -α5β1, and -α5 antibody blocking assay 
showed that RGD-modified PEGylated liposomes were 
internalized by integrin receptor-mediated endocytosis in the 
retinal pigment epithelial cells. However, the fluorescence 
of FAM-siRNA-loaded 1 mol% RGD-PEGylated liposomes 
was not completely inhibited by pretreating the cells with 
blocking antibodies against αVβ3, α5β1, and α5 integrins 
(Figure 7). The integrin family includes not only αVβ3 and 
α5β1, but also α8β1, α11bβ3, αVβ6, and αVβ8, which recognize 
RGD-containing peptides.42
Conclusion
The results of this study showed successful synthesis of the 
functional lipid, DSPE-PEG-RGD, which could be incor-
porated into a liposome formulation that was prepared and 
loaded with siRNA for effective delivery into ARPE-19 cells. 
The prepared siRNA-loaded 1 mol% RGD-PEGylated 
liposomes demonstrated a positive charge (24.9 ± 1.5 mV), 
a nanosize of 156.4 nm (with narrow distribution width 
of 37.5 nm), entrapment efficiency (98.83% ± 0.01%), 
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Figure 7 effect of antibodies on cell integrin receptors and uptake of 1 mol% rgD-Pegylated liposomes by ArPe-19 cells: The cells were incubated with FAM-sirNA -loaded 
1 mol% Pegylated liposomes after one hour of blocking with antibody.
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low cytotoxicity, and a high level of siRNA delivery 
efficiency compared with other investigated liposome 
vehicles. The antibody blocking assay results confirm that 
receptor-mediated endocytosis was involved in the cell 
uptake of the RGD-PEGylated liposomes and the loaded 
siRNA. These results provide a methodology for siRNA-
specific delivery to retinal pigment epithelial cells using 
RGD-modified PEGylated liposomes.
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